Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20080102034 A1
Publication typeApplication
Application numberUS 11/763,125
Publication date1 May 2008
Filing date14 Jun 2007
Priority date26 Mar 2001
Also published asCA2442080A1, CA2442080C, CN1261165C, CN1494435A, CN1824311A, CN1899614A, CN1899614B, CN1899615A, CN1899615B, CN1935277A, CN1935277B, CN100379456C, DE10115740A1, DE20122582U1, DE20122735U1, DE20122736U1, DE50110649D1, DE50112886D1, DE50112978D1, DE50115417D1, EP1372737A2, EP1372737B1, EP1372737B8, EP1666070A1, EP1666070B1, EP1666071A1, EP1666071B1, EP1669092A1, EP1669092B1, US7750041, US8389043, US9066990, US20050101522, US20050250672, US20080102033, US20100278744, US20100278997, US20140227192, US20140227193, US20140227194, WO2002076509A2, WO2002076509A3
Publication number11763125, 763125, US 2008/0102034 A1, US 2008/102034 A1, US 20080102034 A1, US 20080102034A1, US 2008102034 A1, US 2008102034A1, US-A1-20080102034, US-A1-2008102034, US2008/0102034A1, US2008/102034A1, US20080102034 A1, US20080102034A1, US2008102034 A1, US2008102034A1
InventorsUlrich Speck, Bruno Scheller
Original AssigneeUlrich Speck, Bruno Scheller
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Preparation for the prophylaxis of restenosis
US 20080102034 A1
Abstract
The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water .gtoreq.0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.
Images(6)
Previous page
Next page
Claims(15)
1. A preparation containing at least one antihyperplastic agent with a distribution ratio between butanol and water of ≧0.5 in liquid form suitable for passing through capillaries together with an agent for enhancing artery/vein imaging.
2. A preparation containing at least one antihyperplastic agent with a distribution ratio between butanol and water of ≧0.5 that is applied to a catheter.
3. A preparation in aqueous solution that may optionally contain additives as well as at least one antihyperplastic agent with a distribution ratio between butanol and water of ≧0.5 at a concentration that exceeds the saturation concentration in the purely aqueous medium wherein the active agent is not enclosed in micelles.
4. The preparation according to claims 1 through 3 wherein the antihyperplastic agent is a cytostatic, a corticoid, a prostacyclin, an antioxidant, an antibiotic, an agent inhibiting cell proliferation or an immunosuppressant.
5. The preparation according to claims 1 through 4 wherein the antihyperplastic agent is a taxoid.
6. The preparation according to claims 1 through 5 wherein the antihyperplastic agent is paclitaxel, docetaxel, probucol, a porphyrin derivative, colchicine or epithilone.
7. The preparation according to claims 1 through 6 wherein the agent for enhancing artery/vein imaging consists of solutions, suspensions or emulsions that the vessels can tolerate and that are used in X-raying, sonography, optical imaging, or magnetic resonance imaging for improved representation of the blood vessels or the bloodstream.
8. The preparation according to claims 1 through 7 wherein the agent for enhancing artery/vein imaging is an X-ray contrast medium.
9. The preparation according to claims 1 through 8 wherein the agent for enhancing artery/vein imaging is iodixanol (Visipaque), gadolinium-DTPA (Magnevist), Gd-DO3A-butrol (Gadovist), iopromide (Ultravist), iohexol (Omnipaque), or iopamidol (Solutrast).
10. The preparation according to claims 1 through 9, characterized in that the preparation additionally contains coagulation inhibitors and/or platelet aggregation inhibitors and/or enzyme inhibitors and/or calcium chelators.
11. The preparation according to claims 1 through 10 wherein the active agent irreversibly or reversibly binds to tissue at a minimum percentage of 10%.
12. The preparation according to claims 1 through 11 wherein the active agent or the component carrying the active agent comprises a specific affinity to vascular walls.
13. The preparation according to claims 1 through 12 wherein the preparation contains a solubility promoter that does not form micelles.
14. Use of the preparation according to claims 1 through 13 for restenosis prevention.
15. Use of the preparation according to claims 1 through 13 for treating tumor diseases.
Description
  • [0001]
    The invention relates to a preparation for restenosis prevention and its application to an angiography catheter.
  • [0002]
    Stenoses of blood vessels are a major cause of morbidity and morality. Local stenoses or occlusions of larger vessels up to ca. 2 mm in diameter can be dilated back to their original lumen in many instances using inflatable balloon catheters. High pressures are applied when doing this, which may result in lacerations of the thickened vascular walls that are squeezed and displaced into the surrounding tissue. In some of these operations, tubular perforated metal supports (stents) are implanted to keep the vessels open. The vascular walls treated in this way frequently respond by increased growth in thickness that is similar to developing a scar within a few weeks and months. As a result and due to advancing arteriosclerosis, these vessels may relatively soon become stenosed again (restenosis). Restenosis is a severe medical problem that causes high costs.
  • [0003]
    A proven clinical method to prevent restenosis is irradiation of the affected vascular wall sections with a high dosage of X-rays (extracorporal sources or intraluminal radioisotopes) immediately after the surgery.
  • [0004]
    Major disadvantages of irradiation are the required precautions when handling preventive radiation dosages. Many other methods for preventing premature restenosis have been tested in labs and clinical practice but as yet without any major breakthrough [Bult H. Restenosis: A challenge for pharmacology. Tips 21 pp. 274-279, 2000]. Good results were only achieved using drug-releasing stents. For this method to be effective, stents have to be implanted so that restenosis cannot be prevented when the vessel is just dilated and no stent is implanted.
  • [0005]
    Inhibition of mitosis, reactive vascular wall thickening and restenosis has been described for a great number of drugs: Important principles of action are inhibition of platelet aggregation, enzyme inhibition, inhibition of mitosis, cytostatics, and corticoids. Favorable results were achieved in vitro and partly in animal experiments but have not been confirmed in clinical tests. A frequent explanation offered is that active agent concentrations in the affected sections of the vascular wall are insufficient. This is particularly true for oral and intravenous administration where side effects prevent higher doses. As an alternative, administration using specific catheters was attempted wherein these catheters either press the drug solution through the pores of a tight-sitting balloon directly into the vascular wall or block supply and discharge in a vessel section and expose the vessel wall to the drug solution for some time [Herdeg, C., M. Oberhoff, D. I. Siegel-Axel, A. Baumbach, A. Blattner, A. Kuttner, S. Schroder, K. R. Karsch: Paclitaxel: Ein Chemotherapeutikum zur Restenoseprophylaxe? Experimentelle Untersuchungen in vitro und in vivo. Z Kardiol 89 pp. 390-397, 2000]. Drug exposure of previously dilated vessel sections that was effective over a longer period of time was achieved by the slow release of active agents from coated stents. However, the problem of achieving sufficient active agent concentrations over a sufficient exposure time in the vessel sections requiring treatment remains the same with all these methods. Hydrophilic active agents are quickly washed out of tissues [Baumbach, A., C. Herdeg, M. Kluge, M. Oberhoff, M. Lerch, K. K. Haase, C. Wolter, S. Schroder, K. R. Karsch: Local drug delivery: Impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall. Cathet Cardiovasc Intervent 47 pp. 102-106, 1999]. Repeated administration is impossible because of the invasive access using catheters. Lipophilic active agents do not dissolve well enough in vessel-compatible aqueous media or are kept in solution as micelles or liposomes; these micelles or liposomes are only slowly absorbed by the tissue. Administration using special catheters that interrupt the blood flow for some time or press the active agent solution under high pressure into the vascular wall first of all causes additional tissue damage and intensifies reactive hyperplasia.
  • [0006]
    Coated, drug-releasing stents are difficult to produce in constant quality, they contain only very low active agent quantities due to their light weight and delicate design and are not suitable for proximal and distal treatment of the vascular sections at risk of restenosis a few millimeters around the stent. If a stent was implanted at an earlier time, and there is stenosis in its lumen, this can be removed by inflating a balloon catheter. This implantation of a second stent into the lumen of the first stent to prevent vessel wall hyperplasia as a consequence of dilatation is undesirable so that there is no effective method of restenosis prevention for this case. The same applies when there is no indication for implanting a stent after angioplasty or when hyperplastic vessel processes are taking place without clear stenosis of the lumen so that neither vessel dilatation nor stent implantation are required. Some of these vessel wall changes may cause sudden, mostly thrombotic occlusions. In this case, too, a method independent of stent implantation for inhibiting pathological vessel wall changes is desirable.
  • [0007]
    Active agents that were tested with some success in laboratory settings are heparin and hirudin derivatives, prostacyclins, corticoids, rapamycin, colchicine, and paclitaxel.
  • [0008]
    In most cases, the active agents were applied to stents; whenever solutions were used, these were aqueous solutions or, for the poorly water-soluble paclitaxel (4,10-β-diacetoxy-13-α-((2R,3S)-3-ben-zamido-2-hydroxy-3-phenylpropionyloxy)-2α-benzoyloxy-5-β, 20-epoxy-1, 7-β-dihydroxy-11-taxene-9-one), aqueous solutions with an ethanol or cremophor additive. Micelles are formed when using cremophor [poly(oxyethylene)-35-castor oil] that can largely be avoided when using ethanol.
  • [0009]
    Suspensions or emulsions with relatively large-sized particles in aqueous cytostatic solutions with or without an added contrast agent have been described for direct injection into tumor-feeding blood vessels. These preparations are used to close tumor vessels and for simultaneous cytostatic treatment. Closing the vessels is directly opposed to the purpose of this invention.
  • [0010]
    It is the problem of this invention to provide agents for the local treatment of potentially hyperproliferative tissue that can be handled easily and do not harm the patient.
  • [0011]
    Based on the state of the art, this problem is solved according to the invention by a preparation containing at least one antihyperplastic agent with a distribution ratio between butanol and water of ≧0.5, and by inserting said preparation in an agent for enhancing the imaging of arteries and veins or by applying it to a catheter.
  • [0012]
    The concept of the invention is based on the observation that active agents from adequately concentrated solutions, gels or other matrices are absorbed fast and in sufficient quantities by a vessel wall unless they are enclosed in outwardly hydrophilic micelles by solubility promoters. When the active agents are lipophilic (butanol to aqueous buffer solution (pH 7) distribution ratio ≧0.5, preferably ≧1 and ≧5 particularly preferred, or octanol to aqueous buffer solution (pH 7) distribution ratio ≧1, preferably ≧10, and ≧50 particularly preferred), and/or reversibly (>10%, preferably >50%, >80% particularly preferred) and/or irreversibly bind to cell components (such as paclitaxel, probucol (4,4′-(isopropylidenebisthio)bis(2,6-di-tert-butylphenol), porphyrin derivatives), the retention time in the blood vessel when administered during vessel dilatation and optional stent implantation is sufficient for the treatment effect. Prevention of reduction of initial reactive hyperplasia as a consequence of vascular injury prevents the vessel wall from growing too thick over many months. Surprisingly, the preparations according to the invention did not require longer exposure of the tissue to be treated or indirect infiltration and additional injury of the vessel wall.
  • [0013]
    Contrast agents were selectively injected into the affected vessels several times during angioplasty and stent implantation to determine positioning, degree and form of the stenosis, to specify the exact position of the dilatation catheter, evaluate dilatation success, and, optionally, to implant a stent of appropriate thickness and length. By adding the active agents or their preparations that are suited for the purpose to the contrast agents used for diagnostic purposes, the active agent is transferred into the vascular wall with each injection of contrast agent, without additional effort or damage to the vessels. The entire vessel section imaged for diagnostic purposes is treated including the area in front of the stenosis and the area away from its center. This has the major benefit that critical zones upstream and downstream from the dilated stenosis and optional stent implantation are not excluded from treatment.
  • [0014]
    If the injection of contrast media is not required or undesirable, solutions of lipophilic active agents in other aqueous carriers can be used without adding micelle-forming substances. One requirement is that these solutions contain a higher active agent concentration than the saturation concentration in the aqueous medium. This can be achieved by adding organic solvents that form few or no micelles such as ethanol or DMSO and/or by dissolving the active agents under conditions that are not beneficial for storage and administration (e.g. heating, mixing with concentrated active agent solutions in organic solvents) to form sufficiently stable oversaturated solutions.
  • [0015]
    In some cases, solubility of the lipophilic active agents in the contrast agent solutions or the stability of oversaturated solutions are surprisingly improved. Another surprising effect due to the contrast agents is enhanced adhesion and absorption of active agents by vessel walls and good local tolerance of some substances of extreme systemic toxicity in sensitive vessel sections.
  • [0016]
    When active agent and contrast medium are incompatible or when the active agent does not dissolve properly in the contrast medium, the active agent solution can also be directly infused or injected through the diagnostic catheter into the respective vessel. It is preferred to use similar volumes as they are common for vessel imaging using contrast media through catheters [Elke M: Kontrastmittel in der radiologischen Diagnostik, pp. 113-119, 3rd edition, Georg Thieme Verlag Stuttgart New York, 1992].
  • [0017]
    Contrast agents are solutions, suspensions or emulsions well tolerated by vessels that can be used to enhance the representation of blood vessels or the bloodstream in radiograms, sonograms, optical imaging or magnet resonance imaging.
  • [0018]
    These contrast agents include Visipaque 320 (iodixanol), Ultravist 370 (iopromide), Omnipaque 350 (iohexol) or Solutrast 370 (iopamidol) or Magnevist (gadolinium-DPTA) or Gadovist 1M (Gd-DO3A-butrol).
  • [0019]
    Active agents can be all substances suitable for inhibiting cell growth, cell multiplication and hyperplastic proliferation provided they meet the criteria defined above regarding lipophilia and/or binding to tissue components. Inasmuch as some active agents are not sufficiently lipophilic or capable of binding, their pharmacologically active derivatives or precursors of pharmacologically active substances may be used that release the actual active agent when in the tissue only. Preferred are cytostatics from the taxoid group such as paclitaxel and docetaxel ((2R,3S)-N-(tert-butoxycarbonyl)-2-hydroxy-3-phenyl-β-alan-ine-(4-acetoxy-2-α-benzoyloxy-5-β, 20-epoxy-1, 7-β, 10-β-trihydroxy-9-oxo-11-taxene-13-α-yl-ester)), or epothilones as examples of lipophilic substances. These are so lipophilic and insoluble in water that even more hydrophilic derivatives as described by Nicollaou K C, Riemer C, Kerr M A, Rideout D, Wrasidlo W. Design, Synthesis and biological activity of protaxols. Nature, 1993; 364: pp. 464-466 or in U.S. Pat. No. 457,674, Novel Taxoids, are preferred as long as their molecular weight does not exceed ca. 10 kD.
  • [0020]
    Other useful active agents are selected from the groups of corticoids, mitosis inhibitors such as colchicine, antibiotics such as azithromycin or roxithromycin (Gupta et al. 1998) or antioxidants such as probucol, as well as heparin and hirudin derivatives or prostacyclins. Furthermore, immunosuppressants such as rapamycin are among the active agents that can be used.
  • [0021]
    Examples of lipophilic derivatives of otherwise hydrophilic cytostatics can be found in Brunner H, Schellerer K-M, Treittinger B. Synthesis and in vitro testing of hematoporphyrin type ligands in platinum(II) complexes as potent cytostatic and phototoxic antitumor agents. Inorganica Chimica Acta, 1997; 264: pp. 67-79 in the form of conjugates of platinum complexes with porphyrins.
  • [0022]
    The preparations according to the invention that contain a cytostatic as an active ingredient are also suitable for treating tumor diseases. It is advantageous in this case that the treatment is local, which minimizes the strain the patient is put under.
  • [0023]
    Besides lipophilic substances, other active agents or substrate-bound active agents with a specific affinity to vessel walls, particularly to vessel walls showing pathological change, are suitable. Substances have a specific affinity to vessel walls when they are not washed away by the bloodstream within a few minutes. It is known that small concentrations of magnetites are deposited after intravenous administration in vessel walls that show arteriosclerotic change (Schmitz S A et al. Superparamagnetic iron oxide—enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol, 2000; 35: 460-471). However it is surprising that these magnetites reach concentrations sufficient for treatment after a short-time flow through the vessels that are dilated using a balloon. To make these magnetites usable for treatment, they must be coated with drugs as described, for example, by Lubbe A S, Bergemann C, Huhnt W. Fricke T, Riess H, Brock J W, Huhn D. Preclinical experiences with magnetic drug targeting: Tolerance and efficacy. Cancer Research, 1996, 56: 4694-4701).
  • [0024]
    The active agents are dissolved as much as possible in the undiluted contrast agents. They can also be prepared as a separate solution that is diluted with contrast agents prior to use. The mixing ratio of active agent solution and contrast agent solution should not be greater than 2:1, preferably <1:1, <0.2:1 being particularly preferred. The active agent should be dissolved in a well-tolerable aqueous medium or a medium that can be mixed with water. Also admissible are organic solvents that are well tolerated (at least after being diluted with the contrast agent solution or another aqueous medium) such as ethanol, DMSO, DMF, etc. The prepared injection solution will mostly contain as great a portion of water as possible (>90 volume percent, preferred >95 volume percent, >99 volume percent particularly preferred).
  • [0025]
    The concentration range of each active agent is dependent on their solubility in physiologically tolerable solvents without having to resort to micelle-forming agents such as cremophor and on the efficacy and tolerability of the active agents. The upper limit of the concentration is always determined by the volume to be administered (e.g. 100 to 200 ml for repeated injection into the coronary arteries) and the maximum systemically tolerable dose (e.g. ca. 100 mg per sqm body surface for paclitaxel). Preferred and sufficiently effective due to local administration and action are dosages of 1/10th or less of the maximum systemically tolerable dose.
  • [0026]
    Other effective substances such as coagulation inhibitors, platelet aggregation inhibitors, enzyme inhibitors, complex-forming agents for calcium ions, etc. may be added to the preparations. These do not have to meet the criteria for lipophilia, binding to tissue components or molecular weight as the effect can also be acute and intravascular; what has been said in the paragraph regarding concentration and dosage above applies here because the focus is on the local effect in the vessel section through which the preparation flows.
  • [0027]
    Another way of administering antiproliferative agents is provided by a catheter used for vessel dilatation that has an inflatable balloon which itself causes the vascular dilatation. The balloon can be coated with the active agent. When the vessel is dilated, the balloon is pressed against the vessel wall. This provides an opportunity for the active agent to transfer into the vessel wall. If the balloon is used to dilate a stent, even the active agent between the balloon and the stent can be released because the metal struts of the stent are displaced relative to the balloon surface. These variations of active agent administration do not constitute an additional step for the physician as compared to the original process of vessel dilatation or stent implantation.
  • [0028]
    The following methods can be used if the active agents are to be applied to the part of the catheter that is used for vessel dilatation: Dissolution of the active agent(s) in a solvent that does not corrode the catheter, immersion of the respective catheter part in the solution, removal of the catheter from the solution, and drying. Optionally, matrix or gel-forming adjuvants can be added to the active agent solution in the vessel, e.g. lipides or polymers used in pharmacology. Coating can be performed in several steps, while agent-containing and agent-free layers may alternate. The solvents for the respective layers should be selected in such a way that the subsequent coating does not strip off the previous one.
  • [0029]
    The examples below shall explain the invention:
  • EXAMPLES Example 1a Solution for Direct Administration into the Arteries
  • [0030]
    80 mg of 7-(2″,3″-dihydroxypropyl oxycarbonyl)-paclitaxel are dissolved in 5 ml of dimethyl sulfoxide and diluted with 5 ml of a 5% glucose solution. The solution or a part thereof is slowly infused into the previously dilated arteries.
  • Example 1b X-ray Contrast Medium with an Additive for Inhibiting Intimal Hyperplasia
  • [0031]
    99 parts of a portion of the solution described in 1a are added to the Visipaque 320, a commercial X-ray contrast medium, and immediately mixed well. The solution can be used as is common for angiography prior to or after vessel dilatation.
  • Example 2a Solution as an Additive to Contrast Agents
  • [0032]
    200 mg of 7-(2″,3″-dihydroxypropyl oxycarbonyl)-paclitaxel are dissolved in 10 ml of absolute ethanol (=solution A); 0.35 ml of this solution can be added to 100 ml of contrast agent.
  • Example 2b X-ray Contrast Medium for Restenosis Prevention
  • [0033]
    100 ml of Ultravist 370 (Schering AG, Berlin; active ingredient iopromide equivalent to 370 mg of iodine/ml) containing 0.35 volume percent of ethanol and 7 mg of 7-(2″,3″-dihydroxypropyl oxycarbonyl)-paclitaxel. The solution is produced by dissolving the 7-(2″,3″-dihydroxypropyl oxycarbonyl)-paclitaxel in ethanol and adding it under constant stirring to the contrast agent.
  • Example 2c X-ray Contrast Medium for Restenosis Prevention
  • [0034]
    The preparation according to Example 2b with an addition of 10 I.U. of low-molecular heparin
  • Example 2d Restenosis-inhibiting Perfusion Solution
  • [0035]
    3.5 ml of the solution A described in Example 2a are mixed with 46.5 ml of ethanol and added under fast shaking to 1000 ml of warm (˜50.degree. C.) 5% glucose solution or isotonic electrolyte solution. This solution is infused via a catheter into the vessels to be treated just like a contrast medium; however, the infusion rate can be reduced as compared to that of contrast agents.
  • Example 3a X-ray Contrast Medium for Inhibiting Intimal Hyperplasia
  • [0036]
    100 ml of Ultravist 370 (see Example 2b) mixed with 0.4 volume percent of ethanol and 14.4 mg of 7-(2″,3″-dihydroxypropyl oxycarbonyl)-paclitaxel. The preparation is produced as described in Example 2b.
  • Example 4a X-ray Contrast Medium for Inhibiting Cell Growth
  • [0037]
    100 ml of Solutrast 370 (Byk-Gulden, Konstanz; active ingredient iopamidol equivalent to 370 mg of iodine/ml) containing 1.0 volume percent of ethanol and 8.2 mg of paclitaxel/ml. The preparation is produced by first dissolving the paclitaxel in absolute ethanol while heating it slightly, then adding the contrast agent quickly and under strong stirring.
  • Example 4b X-ray Contrast Medium for Inhibiting Intimal Hyperplasia
  • [0038]
    Preparation according to Example 4a plus adding 5 I.U. of heparin and 5 mmol/l of citrate buffer (pH 7.0).
  • Example 5a Solution as an Additive to Contrast Agents or Infusion Solutions
  • [0039]
    20 mg of (±)-trans-1,2-diaminocyclohexane{7,12-bis[1-(1,4,7,10,1-3,16-hexaoxaheptadecyl)-ethyl]-3,8,13,17-tetramethylporphyrin-2,18-dipropionato}platinum(II) are dissolved in 10 ml of dimethyl sulfoxide (=solution B)
  • Example 5b X-ray Contrast Medium with an Additive for Inhibiting Cell Growth
  • [0040]
    1 ml of solution B is added under fast stirring to 100 ml of Ultravist 370 (see Example 2b). The solution is suitable for infusion into arteries or injection into living or dead tissues or body cavities. It allows excellent control of its initial distribution and causes a long-lasting cytostatic effect.
  • Example 5c Contrast Medium for Magnetic Resonance Tomography with an Additive for Inhibiting Cell Growth
  • [0041]
    1 ml of solution B is added to 10 ml of 50 mmolar gadolinium DTPA (=gadopentetate) solution. A 50 mmolar gadolinium-DTPA solution is prepared from Magnevist, a commercial preparation (Schering AG, Berlin), by diluting the product ten times. The solution can be infiltrated, for example, in vital tumors or in tumors after they were destroyed by ethanol, heat or cold treatment. The distribution of the solution is well visible in magnetic resonance tomograms. The solution itself supports the total destruction of the tumor in the immediately infiltrated area and its vicinity.
  • Example 6 In-Vivo Efficacy of the Preparation as Described in Example 2b
  • [0042]
    2 coronary arteries each in a total of 8 pigs were dilated under anesthesia, and stents (fine, heavily perforated metal tubes) were implanted. The arteries respond by wall thickening, which results in narrowing the original lumen of the arteries. 4 pigs were administered a regular X-ray contrast agent (Ultravist 370) for imaging the arteries and checking the stent implantation, 4 pigs were administered the preparation according to Example 2b. The vessels of both test groups practically had the same widths (inside diameters 3.4±0.2 mm and 3.5±0.2 mm) immediately after treatment. 4 weeks after treatment, the inside arterial diameter in animals that only received the regular contrast agent had stenosed by 1.9±0.8 mm, whereas the arterial diameter in the animals that were treated with the solution according to Example 2b was only reduced by 0.9±0.6 mm. This difference is statistically significant (p=0.01). The undiluted solution according to Example 2b was tolerated without side effects despite the addition of a high concentration of a relatively toxic cytostatic after injection in the coronary arteries and simultaneous ECG and blood pressure measurements.
  • Example 7a Coating a Catheter
  • [0043]
    The distal area carrying the balloon of a balloon catheter designed for vessel dilatation is immersed under sterile conditions in the ethanolic solutions from Example 2a (=solution A), kept in the solution for ca. 5 minutes, then removed and dried for 2 hours at room temperature. The balloon catheter can then be used in the common way for dilating vessels.
  • [0044]
    Alternatively, a stent is placed on the balloon after drying.
  • Example 7b
  • [0045]
    The procedure is like in Example 7a, but 100 mg of pharmaceutical castor oil are now added to solution A.
  • Example 8a Solubility in the Contrast Agent or Physiological NaCl Solution
  • [0046]
    7.6 mg of paclitaxel are dissolved in 0.5 mg of ethanol and added at room temperature to 50 ml Ultravist-370 (contains 768 mg of iopromide/ml, specific weight ca. 1.4 g/ml). A clear solution without any turbidity is obtained after mixing that remains stable for several days. No particles can be identified in the solution under a microscope.
  • [0047]
    4.2 mg of paclitaxel are dissolved in 0.5 ml of ethanol and added at room temperature to 50 ml of a 0.9% NaCl solution. The preparation becomes turbid immediately after mixing; most particles are found on the surface of the solution after 2 hours. Large aggregations of fine particles are found using a microscope.
  • [0048]
    Evaluation: The solubility of paclitaxel in the contrast agent is highly surprising. The contrast agent solution contains 0.7 ml of water/ml of solution mixture, i.e. Less solvent is available to paclitaxel in the contrast agent solution than in the NaCl solution. In spite of that, paclitaxel dissolves better in the contrast agent solution than in the NaCl solution.
  • Example 8b Magnetite as the Carrier of the Antihyperplastic Agent
  • [0049]
    75 mg of paclitaxel are dissolved in 5 ml of ethanol. The paclitaxel solution is added to 50 ml of an aqueous preparation of a colloidal magnetite coated with degraded dextrane (concentration refers to Fe2+/3+ 0.5 molar, e.g. SH U 555C, test preparation by Schering AG, Berlin) and quickly intermixed. The magnetite particles adsorb paclitaxel and carry it after intravenous or intra-arterial injection, inter alia, into arterial walls showing arteriosclerotic change and brain tumors. Dosage depends on the use of the magnetite and is ca. 50 μmol referred to Fe/kg of body weight.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4101984 *5 May 197625 Jul 1978Macgregor David CCardiovascular prosthetic devices and implants with porous systems
US4502158 *4 Nov 19825 Mar 1985Masami MouriSlip down-free socks with a garter
US4573476 *14 Nov 19834 Mar 1986Ruiz Oscar FAngiographic catheter
US4677143 *27 Nov 198530 Jun 1987Baxter Travenol Laboratories, Inc.Antimicrobial compositions
US4909799 *18 Sep 198720 Mar 1990Olav ThulesiusMethods for preventing thrombosis; and surgical implant having reduced platelet deposition characteristics
US4917686 *23 Nov 198717 Apr 1990Colorado Biomedical, Inc.Antimicrobial device and method
US4925668 *18 Jan 198915 May 1990Becton, Dickinson And CompanyAnti-infective and lubricious medical articles and method for their preparation
US4994047 *6 May 198819 Feb 1991Menlo Care, Inc.Multi-layer cannula structure
US5004461 *23 Mar 19892 Apr 1991Wilson Joseph EMethods for rendering plastics thromboresistant and product
US5019096 *14 Oct 198828 May 1991Trustees Of Columbia University In The City Of New YorkInfection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US5019393 *3 Aug 198828 May 1991New England Deaconess Hospital CorporationBiocompatible substance with thromboresistance
US5019601 *18 Aug 198928 May 1991Cuno, IncorporatedElastomeric composition containing therapeutic agents and articles manufactured therefrom
US5098977 *24 Dec 199024 Mar 1992Board Of Regents, The University Of Texas SystemMethods and compositions for providing articles having improved biocompatability characteristics
US5102402 *4 Jan 19917 Apr 1992Medtronic, Inc.Releasable coatings on balloon catheters
US5108424 *28 Jan 199128 Apr 1992Meadox Medicals, Inc.Collagen-impregnated dacron graft
US5112457 *23 Jul 199012 May 1992Case Western Reserve UniversityProcess for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants
US5182317 *17 Jun 199126 Jan 1993Cardiopulmonics, Inc.Multifunctional thrombo-resistant coatings and methods of manufacture
US5197977 *30 Apr 199230 Mar 1993Meadox Medicals, Inc.Drug delivery collagen-impregnated synthetic vascular graft
US5217493 *11 Mar 19928 Jun 1993Board Of Regents, The University Of Texas SystemAntibacterial coated medical implants
US5222971 *9 Oct 199029 Jun 1993Scimed Life Systems, Inc.Temporary stent and methods for use and manufacture
US5229172 *19 Jan 199320 Jul 1993Medtronic, Inc.Modification of polymeric surface by graft polymerization
US5282823 *19 Mar 19921 Feb 1994Medtronic, Inc.Intravascular radially expandable stent
US5288711 *28 Apr 199222 Feb 1994American Home Products CorporationMethod of treating hyperproliferative vascular disease
US5298255 *14 Aug 199129 Mar 1994Terumo Kabushiki KaishaAntithrombic medical material, artificial internal organ, and method for production of antithrombic medical material
US5304121 *22 Nov 199119 Apr 1994Boston Scientific CorporationDrug delivery system making use of a hydrogel polymer coating
US5314688 *9 Feb 199324 May 1994Eli Lilly And CompanyLocal delivery of dipyridamole for the treatment of proliferative diseases
US5320634 *17 Apr 199214 Jun 1994Interventional Technologies, Inc.Balloon catheter with seated cutting edges
US5380299 *30 Aug 199310 Jan 1995Med Institute, Inc.Thrombolytic treated intravascular medical device
US5383927 *15 Apr 199324 Jan 1995Intervascular Inc.Non-thromogenic vascular prosthesis
US5383928 *19 Aug 199324 Jan 1995Emory UniversityStent sheath for local drug delivery
US5419760 *11 Oct 199430 May 1995Pdt Systems, Inc.Medicament dispensing stent for prevention of restenosis of a blood vessel
US5500013 *13 Jan 199519 Mar 1996Scimed Life Systems, Inc.Biodegradable drug delivery vascular stent
US5504102 *18 Jan 19952 Apr 1996Bristol-Myers Squibb CompanyStabilized pharmaceutical composition and stabilizing solvent
US5510330 *25 Mar 199423 Apr 1996Boehringer Mannheim GmbhCombinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
US5531716 *29 Sep 19932 Jul 1996Hercules IncorporatedMedical devices subject to triggered disintegration
US5605896 *31 Aug 199425 Feb 1997Recordati S.A., Chemical And Pharmaceutical CompanyBicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
US5607463 *30 Mar 19934 Mar 1997Medtronic, Inc.Intravascular medical device
US5607475 *22 Aug 19954 Mar 1997Medtronic, Inc.Biocompatible medical article and method
US5609629 *7 Jun 199511 Mar 1997Med Institute, Inc.Coated implantable medical device
US5624411 *7 Jun 199529 Apr 1997Medtronic, Inc.Intravascular stent and method
US5626562 *28 Nov 19946 May 1997Devices For Vascular InterventionDrug delivery catheter
US5629008 *7 Jun 199413 May 1997C.R. Bard, Inc.Method and device for long-term delivery of drugs
US5716981 *7 Jun 199510 Feb 1998Angiogenesis Technologies, Inc.Anti-angiogenic compositions and methods of use
US5733327 *17 Oct 199531 Mar 1998Igaki; KeijiStent for liberating drug
US5762638 *14 Feb 19969 Jun 1998Shikani; Alain H.Anti-infective and anti-inflammatory releasing systems for medical devices
US5766158 *31 May 199616 Jun 1998Surface Solutions Laboratories, Inc.Medical apparatus with scratch-resistant coating and method of making same
US5770198 *17 Jan 199523 Jun 1998The Research Foundation Of The State Of New YorkPlatelet-specific chimeric 7E3 immunoglobulin
US5772640 *5 Jan 199630 Jun 1998The Trustees Of Columbia University Of The City Of New YorkTriclosan-containing medical devices
US5863745 *5 Jun 199526 Jan 1999The United States Of America As Represented By The Department Of Health And Human ServicesRecombinant antibody-toxin fusion protein
US5873904 *24 Feb 199723 Feb 1999Cook IncorporatedSilver implantable medical device
US5886026 *7 Jun 199523 Mar 1999Angiotech Pharmaceuticals Inc.Anti-angiogenic compositions and methods of use
US5902283 *26 Mar 199711 May 1999Baylor College Of Medicine Board Of RegentsAntimicrobial impregnated catheters and other medical implants
US5916596 *1 Oct 199629 Jun 1999Vivorx Pharmaceuticals, Inc.Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6017948 *30 Oct 199825 Jan 2000Supergen, Inc.Water-miscible pharmaceutical compositions
US6039721 *3 Dec 199721 Mar 2000Cordis CorporationMethod and catheter system for delivering medication with an everting balloon catheter
US6064624 *12 Apr 199916 May 2000Micron Technology, Inc.Circuit and method for eliminating idle cycles in a memory device
US6171232 *26 Jun 19979 Jan 2001Cordis CorporationMethod for targeting in vivo nitric oxide release
US6177061 *21 Oct 199923 Jan 2001Nycomed Imaging AsContrast agents comprising an azeotropic mixture of two gases for ultrasound investigations
US6191619 *24 Aug 199920 Feb 2001Analog Devices, Inc.Translators and methods for converting differential signals to single-ended signals
US6203487 *31 Dec 199820 Mar 2001Thomas Jefferson UniversityUse of magnetic particles in the focal delivery of cells
US6207133 *4 Jun 199827 Mar 2001Max-Delbrück-Centrum für Molekulare MedizinAnti-tumoral therapy agent containing a contrast agent
US6214333 *26 Jan 199810 Apr 2001Texas Heart InstituteVasoprotective recombinant adenovirus vector containing a human TFPI gene
US6221467 *7 May 199924 Apr 2001Scimed Life Systems, Inc.Coating gradient for lubricious coatings on balloon catheters
US6231615 *18 Oct 199915 May 2001Parallax Medical, Inc.Enhanced visibility materials for implantation in hard tissue
US6240616 *15 Apr 19975 Jun 2001Advanced Cardiovascular Systems, Inc.Method of manufacturing a medicated porous metal prosthesis
US6248100 *14 May 199919 Jun 2001Scimed Life Systems, Inc.Drainage catheter delivery system
US6335029 *3 Dec 19981 Jan 2002Scimed Life Systems, Inc.Polymeric coatings for controlled delivery of active agents
US6355058 *30 Dec 199912 Mar 2002Advanced Cardiovascular Systems, Inc.Stent with radiopaque coating consisting of particles in a binder
US6364856 *14 Apr 19982 Apr 2002Boston Scientific CorporationMedical device with sponge coating for controlled drug release
US6369039 *3 Dec 19989 Apr 2002Scimed Life Sytems, Inc.High efficiency local drug delivery
US6375931 *14 Apr 199923 Apr 2002Nycomed Imaging AsContrast agents
US6503954 *21 Jul 20007 Jan 2003Advanced Cardiovascular Systems, Inc.Biocompatible carrier containing actinomycin D and a method of forming the same
US6515016 *1 Dec 19974 Feb 2003Angiotech Pharmaceuticals, Inc.Composition and methods of paclitaxel for treating psoriasis
US6544223 *5 Jan 20018 Apr 2003Advanced Cardiovascular Systems, Inc.Balloon catheter for delivering therapeutic agents
US6544544 *8 Aug 20018 Apr 2003Angiotech Pharmaceuticals, Inc.Anti-angiogenic compositions and methods of use
US6562024 *11 May 200113 May 2003Scimed Life Systems, Inc.Drainage catheter delivery system
US6682545 *5 Oct 200027 Jan 2004The Penn State Research FoundationSystem and device for preventing restenosis in body vessels
US6682546 *9 May 200227 Jan 2004Aga Medical CorporationIntravascular occlusion devices
US6695811 *8 Oct 200224 Feb 2004Cardeon CorporationAortic catheter with porous aortic arch balloon
US6706892 *6 Sep 200016 Mar 2004Conjuchem, Inc.Pulmonary delivery for bioconjugation
US6730064 *7 May 20014 May 2004Cook IncorporatedCoated implantable medical device
US6867190 *12 Jul 200115 Mar 2005The Board Of Regents, The University Of Texas SystemMethods of therapy with thrombin derived peptides
US7060051 *24 Sep 200213 Jun 2006Scimed Life Systems, Inc.Multi-balloon catheter with hydrogel coating
US20020032414 *7 May 200114 Mar 2002Ragheb Anthony O.Coated implantable medical device
US20030028243 *14 Aug 20026 Feb 2003Cook IncorporatedCoated implantable medical device
US20030028244 *14 Aug 20026 Feb 2003Cook IncorporatedCoated implantable medical device
US20030036794 *19 Aug 200220 Feb 2003Cook IncorporatedCoated implantable medical device
US20030059454 *24 Sep 200227 Mar 2003Barry James J.Optimized dosing for drug coated stents
US20030100600 *15 Oct 200229 May 2003The Gov't Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health And Human ServiceMethod for treating atherosclerosis or restenosis using microtubule stabilizing agent
US20040068241 *8 Apr 20038 Apr 2004Fischer Frank J.Implantable medical device
US20040073284 *14 Jul 200315 Apr 2004Cook IncorporatedCoated medical device
US20050010522 *9 Jul 200413 Jan 2005Finalabo Co., Ltd.Management system for open position with indication for loss cut and held stock management system with indication for loss cut
US20050042295 *13 Oct 200424 Feb 2005Hunter William L.Anti-angiogenic compositions and methods of use
US20050123605 *7 Oct 20049 Jun 2005Angiotech Pharmaceuticals, Inc.Anti-angiogenic compositions and methods of use
US20060020243 *26 Aug 200326 Jan 2006Ulrich SpeckMedical device for dispensing medicaments
US20060020331 *23 Sep 200526 Jan 2006Cook IncorporatedCoated medical device
US20070128118 *1 Dec 20067 Jun 2007Nitto Denko CorporationPolyglutamate-amino acid conjugates and methods
US20080102033 *14 Jun 20071 May 2008Ulrich SpeckPreparation for the prophylaxis of restenosis
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US775004120 Dec 20016 Jul 2010Bayer Schering Pharma AktiengesellschaftPreparation for the prophylaxis of restenosis
US811442917 Mar 201014 Feb 2012Cv Ingenuity Corp.Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US812895124 Feb 20106 Mar 2012Cv Ingenuity Corp.Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US825730526 Aug 20034 Sep 2012Bayer Pharma AktiengesellschaftMedical device for dispensing medicaments
US825772215 Sep 20084 Sep 2012Cv Ingenuity Corp.Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US83666607 Mar 20115 Feb 2013Lutonix, Inc.Drug releasing coatings for medical devices
US83666627 Mar 20115 Feb 2013Lutonix, Inc.Drug releasing coatings for medical devices
US838904313 Jul 20105 Mar 2013Bayer Pharma AktiengesellschaftPreparation for restenosis prevention
US84039107 Mar 201126 Mar 2013Lutonix, Inc.Drug releasing coatings for medical devices
US84043007 Mar 201126 Mar 2013Lutonix, Inc.Drug releasing coatings for medical devices
US841452516 May 20089 Apr 2013Lutonix, Inc.Drug releasing coatings for medical devices
US841452620 May 20089 Apr 2013Lutonix, Inc.Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US841490919 Nov 20079 Apr 2013Lutonix, Inc.Drug releasing coatings for medical devices
US841491025 Mar 20109 Apr 2013Lutonix, Inc.Drug releasing coatings for medical devices
US842545920 May 200823 Apr 2013Lutonix, Inc.Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US843005527 Aug 200930 Apr 2013Lutonix, Inc.Methods and apparatuses for coating balloon catheters
US843986819 May 201014 May 2013Bayer Pharma AGMedical device for dispersing medicaments
US846994312 Oct 201025 Jun 2013Cook Medical Technologies LlcCoated implantable medical device
US84919252 Dec 201123 Jul 2013Cv Ingenuity Corp.Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US85630232 Dec 201122 Oct 2013Covidien LpLocal delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US859772021 Jan 20083 Dec 2013Hemoteq AgMedical product for treating stenosis of body passages and for preventing threatening restenosis
US866936023 Sep 201111 Mar 2014Boston Scientific Scimed, Inc.Methods of converting amorphous drug substance into crystalline form
US867333227 Jul 201218 Mar 2014Covidien LpLocal delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US873482517 Jun 201327 May 2014Covidien LpLocal delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US88892112 Sep 201118 Nov 2014Boston Scientific Scimed, Inc.Coating process for drug delivery balloons using heat-induced rewrap memory
US893256118 Mar 201313 Jan 2015Lutonix, Inc.Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US899884614 Mar 20137 Apr 2015Lutonix, Inc.Drug releasing coatings for balloon catheters
US899884718 Mar 20137 Apr 2015Lutonix, Inc.Drug releasing coatings for medical devices
US900516118 Mar 201314 Apr 2015Lutonix, Inc.Drug releasing coatings for medical devices
US902337118 Mar 20135 May 2015Lutonix, Inc.Drug releasing coatings for medical devices
US903391918 Mar 201319 May 2015Lutonix, Inc.Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US90343628 Jan 201419 May 2015The Spectranetics CorporationLocal delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US905615223 Sep 201116 Jun 2015Boston Scientific Scimed, Inc.Medical device with crystalline drug coating
US906699013 Jul 201030 Jun 2015Bayer Intellectual Property GmbhPreparation for restenosis prevention
US913221116 Apr 201415 Sep 2015The Spectranetics CorporationLocal delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US918048518 Mar 201310 Nov 2015Lutonix, Inc.Methods and apparatuses for coating balloon catheters
US91926979 Feb 201124 Nov 2015Hemoteq AgBalloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US919896811 Sep 20091 Dec 2015The Spectranetics CorporationLocal delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US92482204 Dec 20142 Feb 2016Lutonix, Inc.Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US92833582 Apr 201515 Mar 2016Lutonix, Inc.Drug releasing coatings for medical devices
US928953720 Apr 201522 Mar 2016Lutonix, Inc.Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids
US928953910 Apr 201522 Mar 2016Lutonix, Inc.Drug releasing coatings for medical devices
US931455217 Apr 201519 Apr 2016Lutonix, Inc.Drug releasing coatings for medical devices
US93145982 Apr 201519 Apr 2016Lutonix, Inc.Drug releasing coatings for balloon catheters
US940293528 May 20132 Aug 2016Lutonix, Inc.Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US960397314 Sep 201528 Mar 2017The Spectranetics CorporationLocal delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US964947619 Apr 201316 May 2017Bayer Intellectual Property GmbhMedical device for dispersing medicaments
US969411129 Jan 20164 Jul 2017Lutonix, Inc.Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US970070413 May 201611 Jul 2017Lutonix, Inc.Drug releasing coatings for balloon catheters
US973764013 May 201622 Aug 2017Lutonix, Inc.Drug releasing coatings for medical devices
US973769113 May 201622 Aug 2017Lutonix, Inc.Drug releasing coatings for balloon catheters
US975735111 Mar 201612 Sep 2017Lutonix, Inc.Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids
US975754411 Mar 201612 Sep 2017Lutonix, Inc.Drug releasing coatings for medical devices
US976406510 Mar 201619 Sep 2017Lutonix, Inc.Drug releasing coatings for medical devices
US97705764 Nov 201526 Sep 2017Lutonix, Inc.Methods and apparatuses for coating balloon catheters
US20050101522 *20 Dec 200112 May 2005Ulrich SpeckPreparation for the prophylaxis of restenosis
US20050250672 *20 Dec 200110 Nov 2005Ulrich SpeckPreparation for the prophylaxis of restenosis
US20080102033 *14 Jun 20071 May 2008Ulrich SpeckPreparation for the prophylaxis of restenosis
US20080304101 *20 May 200811 Dec 2008Naoko SasaseServer and printer introducing method under thin client environment
US20100068170 *11 Sep 200918 Mar 2010Michal Eugene TLocal delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US20100228228 *19 May 20109 Sep 2010Ulrich SpeckMedical device for dispersing medicaments
US20100278997 *13 Jul 20104 Nov 2010Ulrich SpeckPreparation for restenosis prevention
US20110046723 *12 Oct 201024 Feb 2011Bates Brian LCoated implantable medical device
Classifications
U.S. Classification424/9.3, 424/9.5, 514/449, 424/9.1, 514/712, 424/9.4, 514/629
International ClassificationA61L29/16, A61K9/08, A61K45/06, A61P43/00, A61K9/50, A61P9/10, A61P7/02, A61K9/00, A61K45/00, A61K49/18, A61P35/00, A61K49/06, A61K31/165, A61K49/22, A61P9/00, A61K49/00, A61K31/337, A61K49/04, A61K31/095
Cooperative ClassificationA61K49/18, A61K9/0019, A61K45/06, A61K49/0452, A61L2300/416, A61K31/165, A61K49/0447, A61K49/105, A61K49/106, A61K31/337, A61K31/095, A61K9/5094, A61L31/16, A61K49/0438, A61K49/0433, A61L29/16, A61L29/18, A61L29/08
European ClassificationA61K49/10C4G, A61K49/10C8, A61K45/06, A61K9/00M5, A61L31/16, A61K49/18, A61L29/16, A61K49/04H8B, A61K9/50T, A61K49/04H8, A61L29/18, A61K31/337, A61K31/165, A61K31/095, A61K49/04H2